US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Terminated

Curaplex Epi Safe Kit

Reason Labeling Incorrect Instructions: This recall has been initiated because the Instructions for Use included in the Epi-Safe Kits for the Epi-Safe Syringe (and/or the Safety Lok Syringe in Model 8600-01120) recommend a midpoint dosage of epinephrine for children between 0 lbs. and 66 lbs. of 0.15mL that has not been approved by FDA for children. Reliance on the current IFU and/or use of the Epi-Safe Syringe as instructed may result in the administration of an inappropriate dosage of epinephrine to young children experiencing anaphylaxis, especially those under 33 lbs. Additionally the Epi Safe syringe does not have the correct markings to allow a health care provider to draw up the correct dosage for children under 33 kg.

Bound Tree Medical, LLC D-0385-2019
Class II · Moderate risk Terminated

curaplex Epi Safe Kit

Reason Labeling Incorrect Instructions: This recall has been initiated because the Instructions for Use included in the Epi-Safe Kits for the Epi-Safe Syringe (and/or the Safety Lok Syringe in Model 8600-01120) recommend a midpoint dosage of epinephrine for children between 0 lbs. and 66 lbs. of 0.15mL that has not been approved by FDA for children. Reliance on the current IFU and/or use of the Epi-Safe Syringe as instructed may result in the administration of an inappropriate dosage of epinephrine to young children experiencing anaphylaxis, especially those under 33 lbs. Additionally the Epi Safe syringe does not have the correct markings to allow a health care provider to draw up the correct dosage for children under 33 kg.

Bound Tree Medical, LLC D-0384-2019
Class II · Moderate risk Terminated

curaplex Epi Safe Administration and Training Kits

Reason Labeling Incorrect Instructions: This recall has been initiated because the Instructions for Use included in the Epi-Safe Kits for the Epi-Safe Syringe (and/or the Safety Lok Syringe in Model 8600-01120) recommend a midpoint dosage of epinephrine for children between 0 lbs. and 66 lbs. of 0.15mL that has not been approved by FDA for children. Reliance on the current IFU and/or use of the Epi-Safe Syringe as instructed may result in the administration of an inappropriate dosage of epinephrine to young children experiencing anaphylaxis, especially those under 33 lbs. Additionally the Epi Safe syringe does not have the correct markings to allow a health care provider to draw up the correct dosage for children under 33 kg.

Bound Tree Medical, LLC D-0383-2019
Class II · Moderate risk Terminated

IRBESARTAN Tablets

Reason CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodiethylamine (NDEA) in product.

Golden State Medical Supply Inc. NDC 60429-642-30 D-0265-2019
Class II · Moderate risk Terminated

IRBESARTAN Tablets

Reason CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodiethylamine (NDEA) in product.

Golden State Medical Supply Inc. NDC 60429-641-30 D-0264-2019
Class II · Moderate risk Terminated

IRBESARTAN Tablets

Reason CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodiethylamine (NDEA) in product.

Golden State Medical Supply Inc. NDC 60429-640-90 D-0263-2019
Class II · Moderate risk Terminated

Isosorbide Dinitrate Tablets

Reason Cross Contamination with Other Products

Sandoz Inc NDC 68001-222-00 D-0261-2019
Class II · Moderate risk Terminated

Isosorbide Dinitrate Tablets

Reason Cross Contamination with Other Products

Sandoz Inc NDC 68001-225-00 D-0260-2019
Class II · Moderate risk Terminated

Isosorbide Dinitrate Tablets

Reason Cross Contamination with Other Products

Sandoz Inc NDC 68001-223-00 D-0259-2019
Class II · Moderate risk Terminated

Isosorbide Dinitrate Tablets

Reason Cross Contamination with Other Products

Sandoz Inc NDC 0781-1695-01 D-0258-2019
Class II · Moderate risk Terminated

curaplex Epi Safe Administration and Training Kits # 8600-01100…

Reason Labeling: Incorrect or Missing Lot and/or Exp date: vials of epinephrine within kit 8600-01100 expired on December 2018, but the outer kit label has an expiration date of January 2020. In addition, device component (syringe) may lack 510(k) clearance.

Bound Tree Medical, LLC D-0371-2019
Class II · Moderate risk Ongoing

Sandoz Losartan Potassium and Hydrochlorothiazide Tablets

Reason CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Sandoz, Inc NDC 0781-5207-10 D-0359-2019
Class II · Moderate risk Terminated

Bevacizumab 2.5 Mg/0.1ml

Reason Lack of Assurance of Sterility

Avella of Deer Valley, Inc. Store 38 NDC 42852-001-24 D-0224-2019
Class II · Moderate risk Terminated

Omnipaque

Reason Defective Container: vial defect was identified that could potentially impact the container closure and result in a lack of sterility assurance and/or the potential for glass particles.

GE Healthcare Inc. Life Sciences NDC 0407-1411-20 D-0319-2019
Class II · Moderate risk Terminated

Westminster Irbesartan Tablets

Reason CGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan.

Westminster Pharmaceuticals Llc NDC 69367-121-01 D-0302-2019
Class II · Moderate risk Terminated

Westminster Irbesartan Tablets

Reason CGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan.

Westminster Pharmaceuticals Llc NDC 69367-120-01 D-0301-2019
Class II · Moderate risk Terminated

Westminster Irbesartan Tablets

Reason CGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan.

Westminster Pharmaceuticals Llc NDC 69367-119-01 D-0300-2019
Class II · Moderate risk Terminated

GSMS Irbesartan Tablets

Reason CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Sciegen Pharmaceuticals Inc NDC 60429-642-30 D-0272-2019
Class II · Moderate risk Terminated

GSMS Irbesartan Tablets

Reason CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Sciegen Pharmaceuticals Inc NDC 60429-641-30 D-0271-2019
Class II · Moderate risk Terminated

GSMS Irbesartan Tablets

Reason CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Sciegen Pharmaceuticals Inc NDC 60429-640-90 D-0270-2019
Class II · Moderate risk Terminated

Westminister Irbesartan Tablets

Reason CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Sciegen Pharmaceuticals Inc NDC 69367-121-01 D-0269-2019
Class II · Moderate risk Terminated

Westminister Irbesartan Tablets

Reason CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Sciegen Pharmaceuticals Inc NDC 69367-120-01 D-0268-2019
Class II · Moderate risk Terminated

Westminister Irbesartan Tablets

Reason CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Sciegen Pharmaceuticals Inc NDC 69367-119-01 D-0267-2019
Class II · Moderate risk Terminated

Alcohol Free Foaming Hand Sanitizer

Reason CGMP Deviations: Product was released to market prior to microbiological testing.

S.C. Johnson Professional D-0221-2019
Class II · Moderate risk Terminated

deb stoko

Reason CGMP Deviations: Product was released to market prior to microbiological testing.

S.C. Johnson Professional NDC 11084-010-27 D-0220-2019